June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Accelerated healing of corneal endothelial lesions in organ culture by the engineered fibroblast growth factor TTHX1114
Author Affiliations & Notes
  • David Eveleth
    Trefoil Therapeutics, San Diego, California, United States
  • Sarah Pizzuto
    Trefoil Therapeutics, San Diego, California, United States
  • Jessica Weant
    Trefoil Therapeutics, San Diego, California, United States
  • Jennifer Jenkins-Eveleth
    Trefoil Therapeutics, San Diego, California, United States
  • Natalie A Afshari
    Shiley Eye Center, University of California, San Diego, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   David Eveleth, Trefoil Therapeutics (E), Trefoil Therapeutics (I), Trefoil Therapeutics (P); Sarah Pizzuto, Trefoil Therapeutics (E); Jessica Weant, Trefoil Therapeutics (E), Trefoil Therapeutics (I); Jennifer Jenkins-Eveleth, Trefoil Therapeutics (E), Trefoil Therapeutics (I), Trefoil Therapeutics (P); Natalie Afshari, Trefoil Therapeutics (I)
  • Footnotes
    Support  NIH NCATS TRND CRADA# 2016-04
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3255. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Eveleth, Sarah Pizzuto, Jessica Weant, Jennifer Jenkins-Eveleth, Natalie A Afshari; Accelerated healing of corneal endothelial lesions in organ culture by the engineered fibroblast growth factor TTHX1114. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3255.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Corneal endothelial dystrophies are the most common reason for corneal transplantation, but are limited by the supply of suitable donor tissue. Corneal endothelial dystrophy is currently being experimentally treated with limited descemet’s stripping (Descemet's stripping only or DSO) without transplantation. DSO has a slower recovery and a lower success rate than transplantation. This work sought to test whether recovery from DSO and the healing of the endothelial lesions could be accelerated in corneal organ culture by treatment with an engineered form of FGF1 (TTHX1114).

Methods : Rabbit and human corneas were maintained in organ culture. Lesions to the endothelial layer were created either by treatment with octanol, which eliminates the endothelial cells but leaves Descemet’s membrane, or by surgical removal of Descemets. Both processes were performed to create ~4mm central lesions. Corneas were then incubated in the presence or absence of TTHX1114 and the recovery of the endothelial layer evaluated by trypan blue staining.

Results : Both types of lesions become progressively smaller over time. In the rabbit cornea following octanol lesioning, the % of the lesion healed in TTHX1114 treated corneas was 45% vs 29% in the control (p<0.05) after 72 hours. Healing of human corneas after Descemet’s stripping proceeds more slowly but is also accelerated by TTHX1114.

Conclusions : The healing of endothelial lesions, including both with and without the stripping of the underlying Descemet’s membrane, can be accelerated by engineered FGF1 in the organ culture system.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×